EXR
22
-17
VZ
55
5
IVZ
68
15
A
48
-3
SBUX
40
-3
VIX
40
2
WYNN
37
-5
WFC
71
2
ACN
56
-3
VLO
55
-3
HUM
33
-3
ABBV
57
-2
PNR
60
-5
DTE
42
2
MCHP
50
-2
GILD
49
-2
FITB
75
3
AMGN
36
-3
MA
43
-3
CCI
36
2
EXR
22
-17
VZ
55
5
IVZ
68
15
A
48
-3
SBUX
40
-3
VIX
40
2
WYNN
37
-5
WFC
71
2
ACN
56
-3
VLO
55
-3
HUM
33
-3
ABBV
57
-2
PNR
60
-5
DTE
42
2
MCHP
50
-2
GILD
49
-2
FITB
75
3
AMGN
36
-3
MA
43
-3
CCI
36
2
Financhill
Back

Vistagen Therapeutics, Inc. 10K Form

Buy
53

VTGN
Vistagen Therapeutics, Inc.

Last Price:
$4.28
Seasonality Move:
20.93%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive VTGN News And Ratings

See the #1 stock for the next 7 days that we like better than VTGN

VTGN Financial Statistics

Sales & Book Value

Annual Sales: $486K
Cash Flow: $-13.8M
Price / Cash Flow: 0
Annual Sales: $1.71
Price / Book: 2.55

Profitability

EPS (TTM): -1.89780
Net Income (TTM): $-61.6M
Gross Margin: $-149K
Return on Equity: -76.57%
Return on Assets: -67.18%

Vistagen Therapeutics, Inc. Earnings Forecast

Key Vistagen Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 8 years for VTGN is -30.66%.
  • The Selling, General & Administrative Expenses for VTGN have been equal to 3,515.23% of Gross Profit Margin.
  • The Research & Development expenses have been 8,101.85% of Revenue.
  • The Net Earning history of VTGN is -10,579.84% of Total Revenues.
  • Per Share Earnings over the last 17 years have been positive in 8 years.

Vistagen Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: VTGN
CUSIP: 92840H
Website: vistagen.com

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 5.79
Quick Ratio: 5.66

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VTGN Technical Analysis vs Fundamental Analysis

Buy
53
Vistagen Therapeutics, Inc. (VTGN) is a Buy

Is Vistagen Therapeutics, Inc. a Buy or a Sell?